Biognosys pioneers AI-powered proteomics to provide the deepest proteome coverage with industry-leading cost-efficiency

Unprecedented progress in Artificial Intelligence (AI)-enhanced data analysis with Spectronaut® expedites the performance and affordability of TrueDiscovery™ proteomics research services

June 23, 2022. CAMBRIDGE, Mass. and ZURICH. Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today that their TrueDiscovery research services platform now offers the deepest proteome coverage available with industry-leading cost-efficiency.

TrueDiscovery studies now offer insights on 4,200 proteins in plasma, 11,000 proteins in other biofluids, and 13,800 proteins in tissue, covering all relevant disease pathways. These significant gains are driven to a large extent by unprecedented leaps in performance and efficiency with Spectronaut 16, the latest version of Biognosys' flagship software for unbiased proteomics data analysis.

"Our improved TrueDiscovery research services are more attractive and accessible than ever. They can easily be integrated into biopharma research, from small pilot projects to large-scale clinical trials and population health studies," **Kristina Beeler, Ph.D., Chief Business Officer of Biognosys,** commented.

In the latest Spectronaut release, launched at the American Society for Mass Spectrometry (ASMS) 2022 Annual Meeting, the software has undergone one of its most transformative upgrades, with significantly expanded integration of Artificial Intelligence and Machine Learning (AI/ML), enabling improved protein identification and quantification.

Further, Biognosys now deploys their proprietary protein libraries – the industry's largest and highest quality protein inventory, including nearly 100,000 peptide-level data points from biofluid samples and 400,000 data points from tissue samples. These improvements increase the proteome coverage and help optimize the cost-efficiency of study designs, making the platform more accessible across different study sizes.

"Through our expanded AI/ML integration in Spectronaut and our unique peptide-level protein libraries, we once more break the boundary of the proteome coverage in our discovery proteomics services," said **Lukas Reiter, Ph.D., Chief Technology Officer at Biognosys**.

Biognosys is now leveraging these performance and efficiency benefits to make TrueDiscovery services more accessible for drug development and clinical research and offer them at attractive pricing.

About TrueDiscovery™

The Biognosys TrueDiscovery platform offers integrated proteomics solutions across the entire drug development pipeline.

TrueDiscovery is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, an advanced Data Independent Acquisition (DIA)-based protein quantification technology co-invented and patented by Biognosys.

TrueDiscovery is the only platform that searches the complete proteome to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms. The platform enables the deepest unbiased profiling of tissue and biofluids proteomes with unbeatable specificity on a large scale. The generated data are highly reproducible and easily transferrable to clinical assays. Studies can be performed in a GLP certified and GCP compliant environment. For more information, visit truediscovery.bio.

About Spectronaut®

Spectronaut is Biognosys' flagship data analysis software for data-independent acquisition (DIA) mass spectrometry (MS) based proteomics.

The software employs advanced Search, Artificial Intelligence (AI), and Machine Learning (ML) algorithms to translate data into actionable insights for life science research. Spectronaut enables reproducible and precise quantification of thousands of proteins in a single experiment and provides multidimensional insights into protein expression, function, and structure across all major biological species and sample types. For more information, visit spectronaut.com.

About Biognosys

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary next-generation proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut®. These solutions provide a multidimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys' unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit biognosys.com.

Biognosys AG
Wagistrasse 21
8952 Schlieren (Zurich)
Switzerland

t: +41 (0) 44 738 20 40
f: +41 (0) 44 738 20 49
info@biognosys.com
www.biognosyscom

Media Contact

Yves Serroen
Head of Marketing and Communications
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com